Soft-tissue sarcoma (STS) comprises a heterogeneous group of malignant mesenchymal tumors with approximately 70 histological subtypes.1 Leiomyosarcoma (LMS) accounts for approximately 10-20% of STSs and arises frequently in the uterus.2 For patients with metastatic disease, survival after progression on first-line anthracycline-based chemotherapy remains limited, with marked deterioration in health-related quality of life.3
Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma?
Annals of Oncology | | E.A. De Jaeghere, A. Dufresne, L. Azarang, W.T.A. van der Graaf
Topics: sarcoma, chemotherapy, new-technology